Investing.com -- TKO Group Holdings Inc (NYSE: TKO) stock jumped 7.5% following the announcement of a seven-year media rights ...

The threat for SaaS, Melius warned, is that “almost anyone… can create an application so great that it can compete quickly ...

Investing.com -- Morgan Stanley raised its rating on Freeport-McMoRan (NYSE: FCX) to Overweight from Equal-weight, saying the ...

Investing.com -- Kuwait Airways is struggling to meet its strategic targets due to aircraft delivery delays and regional geopolitical pressures, according to Chairman Abdulmohsen Alfagaan on Monday.

Investing.com -- Barrick Mining CEO Mark Bristow said Monday that potential U.S. tariffs on gold bars would have minimal impact on mining companies as they are "price takers." Speaking to Reuters, ...

Investing.com -- Bernstein raised its rating on Sabre (NASDAQ: SABR) to Outperform from Market-perform, saying the market is too pessimistic on the travel technology company’s outlook and is pricing ...

Investing.com -- Viatris Inc (NASDAQ: VTRS) stock rose 2.6% following the U.S. Food and Drug Administration’s approval of the company’s Iron Sucrose Injection, USP, the first generic version of ...

VivoPower will become the first publicly listed company in the United States providing shareholders with exposure to both Ripple shares and XRP tokens. The company will have full legal title to the ...

Investing.com -- C3.ai shares plunged more than 31% premarket Monday after the software maker posted preliminary fiscal first ...

Investing.com -- Amphastar Pharmaceuticals (NASDAQ: AMPH) stock gained 4% after the company announced FDA approval for its generic version of iron sucrose injection, a treatment for iron deficiency ...

Morgan Stanley raised its rating on elf Beauty to Overweight from Equal-weight, saying investor concerns about slowing U.S. sales, price increases and the recent Rhode acquisition have left the stock ...

Investing.com -- IO Biotech (NASDAQ: IOBT) stock rose 6.1% after announcing topline results from its pivotal Phase 3 trial of Cylembio, an investigational cancer vaccine, in combination with Merck ...